MAP2K7 and cancer: APS-2-79 modestly decreased cell viability in two Ras-mutated cancer cell lines (HCT116 and A549) and did not affect Raf-mutated cancer cells (A375 and SK-MEL-293) but did demonstrate substantial synergy in Ras-mutated cancer cells with MEK inhibitors, suggesting the potential to target both kinase and scaffolding components of the Ras signaling pathway in Ras-dependent cancers50.